Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Cancer-related cognitive impairment is a significant concern, yet data assessing long-term changes from pretreatment baselines are limited. METHODS: In this large nationwide study, patients with breast cancer and lymphoma and controls were assessed at pre-chemotherapy, post-chemotherapy, 6-month, 1-year, and 2-year follow-ups. Cognitive function was measured using self-reported and performance-based assessments. The analysis included 225 participants: breast cancer (41 patients/36 controls) and lymphoma (73 patients/75 controls). Cognitive trajectories were estimated using longitudinal linear mixed models, adjusting for demographic, clinical, and psychosocial factors. A minimal clinically important difference cutoff identified changes over time in perceived cognitive impairment. RESULTS: Patients with breast cancer reported greater cognitive complaints than controls, with declines in FACT-Cog Total (β = -17.17, P < .001), Perceived Cognitive Impairment (β = -11.09, P < .001), and Perceived Cognitive Abilities (β = -3.60, P = .03) from pre-chemotherapy to 2-year follow-up. Declines were observed in memory (Rey Auditory Verbal Learning Test [RAVLT] Immediate Recall: β = -1.53, P = .04) and executive function (phone fluency: β = -1.53, P = .02) at 1 year. Patients with lymphoma also showed more complaints, with declines in Perceived Cognitive Impairment (β = -6.19, P = .01), poorer RAVLT Immediate (β = -1.62, P < .001), Delayed Recall (β = -1.72, P < .001), and phone fluency (β = -2.46, P < .001) from pre-chemotherapy to 1-year follow-up. CONCLUSION: Compared with controls, patients with breast cancer and lymphoma showed persistent cognitive worsening up to 1-year posttreatment, and patients with breast cancer reported perceived impairment at 2 years compared with controls.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Longitudinal assessment of cognitive function in patients with breast cancer and lymphoma receiving chemotherapy
- Date Crossref
- 31/10/2025
- Éditeur
- Oxford University Press (OUP)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Rochester Medicine pays non établi dans la noticeÉtablissement de santé
-
University of South Carolina Upstate pays non établi dans la noticeUniversité ou école supérieure
-
Spartanburg Regional Medical Center pays non établi dans la noticeÉtablissement de santé
-
Heartland Cancer Research pays non établi dans la noticeÉtablissement de santé
-
Christiana Care Health System pays non établi dans la noticeÉtablissement de santé
-
University of Rochester Medical Center Department of Surgery pays non établi dans la noticeUniversité ou école supérieure
-
Upstate Carolina National Cancer Institute Community Oncology Research Program pays non établi dans la noticeStructure de recherche
-
Delaware/Christiana Care National Cancer Institute Community Oncology Research Program pays non établi dans la noticeStructure de recherche
-
Wilmot Cancer Institute pays non établi dans la noticeStructure de recherche
University of Rochester Medicine, University of South Carolina Upstate et Spartanburg Regional Medical Center, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.